Summary of clinical experiences with tamsulosin for the treatment of benign prostatic hyperplasia

Abstract

Tamsulosin, a uroselective alpha(1A)-adrenergic-receptor antagonist, has been shown to improve lower urinary tract symptoms associated with benign prostatic hyperplasia. It has a better side effect profile than earlier alpha-adrenergic-receptor antagonists, which were initially developed as antihypertensive agents. Clinical trials of 1 year or longer with tamsulosin show high tolerability for the 0.4 mg dose and no significant interaction with other antihypertensive medications.

Figures

Figure 1

(A) Change in mean ± SD total American Urological Association symptom score from baseline and (B) change in mean ± SD maximum urinary flow from baseline. Both baselines established at first double-blind dose in phase III trial to the endpoint of the extension phase (53 weeks of double-blind therapy). Reproduced and adapted with permission from Lepor et al.